Find information on thousands of medical conditions and prescription drugs.

Multiple myeloma

Multiple myeloma (also known as MM, myeloma, plasma cell myeloma, or as Kahler's disease after Otto Kahler) is a presently incurable hematological malignancy of plasma cells, the cells of the immune system that produce antibodies. Its prognosis despite therapy is generally poor, and treatment may involve chemotherapy and stem cell transplant. more...

Home
Diseases
A
B
C
D
E
F
G
H
I
J
K
L
M
Mac Ardle disease
Macroglobulinemia
Macular degeneration
Mad cow disease
Maghazaji syndrome
Mal de debarquement
Malaria
Malignant hyperthermia
Mallory-Weiss syndrome
Malouf syndrome
Mannosidosis
Marburg fever
Marfan syndrome
MASA syndrome
Mast cell disease
Mastigophobia
Mastocytosis
Mastoiditis
MAT deficiency
Maturity onset diabetes...
McArdle disease
McCune-Albright syndrome
Measles
Mediterranean fever
Megaloblastic anemia
MELAS
Meleda Disease
Melioidosis
Melkersson-Rosenthal...
Melophobia
Meniere's disease
Meningioma
Meningitis
Mental retardation
Mercury (element)
Mesothelioma
Metabolic acidosis
Metabolic disorder
Metachondromatosis
Methylmalonic acidemia
Microcephaly
Microphobia
Microphthalmia
Microscopic polyangiitis
Microsporidiosis
Microtia, meatal atresia...
Migraine
Miller-Dieker syndrome
Mitochondrial Diseases
Mitochondrial...
Mitral valve prolapse
Mobius syndrome
MODY syndrome
Moebius syndrome
Molluscum contagiosum
MOMO syndrome
Mondini Dysplasia
Mondor's disease
Monoclonal gammopathy of...
Morquio syndrome
Motor neuron disease
Motorphobia
Moyamoya disease
MPO deficiency
MR
Mucopolysaccharidosis
Mucopolysaccharidosis...
Mullerian agenesis
Multiple chemical...
Multiple endocrine...
Multiple hereditary...
Multiple myeloma
Multiple organ failure
Multiple sclerosis
Multiple system atrophy
Mumps
Muscular dystrophy
Myalgic encephalomyelitis
Myasthenia gravis
Mycetoma
Mycophobia
Mycosis fungoides
Myelitis
Myelodysplasia
Myelodysplastic syndromes
Myelofibrosis
Myeloperoxidase deficiency
Myoadenylate deaminase...
Myocarditis
Myoclonus
Myoglobinuria
Myopathy
Myopia
Myositis
Myositis ossificans
Myxedema
Myxozoa
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Medicines

Signs and symptoms

Symptoms can include: malaise, bone pain, anemia, infections (due to decreased immunity) and fractures (due to breakdown of bone by malignant cells, as well as a tendency to brittle bones). Often, the diagnosis of multiple myeloma is made incidentally during routine blood tests for other conditions. The antibody that is produced in excess may cause specific medical problems, such as amyloid, acute renal failure and chronic renal failure, polyneuropathy and other disorders.

A mnemonic doctors use to remember the common tetrad of multiple myeloma is CRAB - C = Calcium (elevated), R =Renal failure, A = Anemia, B = Bone lesions.

Diagnosis

Investigations

The existence of unexplained anemia, kidney dysfunction, a high erythrocyte sedimentation rate (ESR) and a high serum protein (especially raised globulin) may suggest further testing. A doctor will then order protein electrophoresis of the blood and urine, on which a paraprotein (monoclonal protein, or M protein) band can be noticed. A type of paraprotein is the Bence Jones protein which is paraprotein composed of free light chains (see below). Quantitative measurements of the paraprotein are necessary to determine the severity of the disease. The paraprotein is a deviant immunoglobulin produced by the tumor clone. Very rarely, the myeloma is nonsecretory (not producing immunoglobulins).

In theory, myeloma can produce all classes of immunoglobulin, but IgD, IgM and IgE myeloma are very rare compared to IgG and IgA. In addition, light and heavy chains (the building blocks of antibodies) may be secreted in isolation: κ- or λ-light chains or any of the five types of heavy chains (α-, γ-, δ-, ε- or μ-heavy chains).

Additional findings are: a raised calcium (when myeloma cells are breaking down bone, releasing calcium into the bloodstream) and decreased renal function, which may be due to paraprotein deposition in the kidney).

Workup

The workup of suspected multiple myeloma includes a skeletal survey. This is a series of X-rays of the skull, axial skeleton and proximal long bones. Myeloma deposits appear as "lytic lesions" (with local disappearance of normal bone due to resorption), and on the skull X-ray as "punched-out lesions". A CT scan may be performed to measure the size of soft tissue plasmacytomas.

A bone marrow biopsy is usually performed to estimate the percentage of bone marrow occupied by plasma cells. This percentage is used in the diagnostic criteria for myeloma. Immunohistochemistry (staining particular cell types using antibodies against surface proteins) can detect plasma cells which express immunoglobulin in the cytoplasm but usually not on the surface; myeloma cells are typically CD56, CD138 positive and CD19 negative. Cytogenetics may also performed in myeloma for prognostic purposes.

Read more at Wikipedia.org


[List your site here Free!]


Proteolytic enzymes beneficial for multiple myeloma - Literature Review & Commentary
From Townsend Letter for Doctors and Patients, 6/1/03 by Alan R. Gaby

Two hundred sixty-five patients with multiple myeloma stages I-Ill were treated with standard chemotherapy. One hundred sixty-six of these patients also received oral enzymes for more than six months, while 99 patients either did not receive enzymes or received them for less than six months (control group). Treatment allocation was not randomized, but was assigned on the basis of the availability of the enzymes on the first day of chemotherapy. The enteric-coated enzyme preparation (Wobe-Mugos) contained 100 mg of papain, 40 mg of trypsin, and 40 mg of chymotrypsin per tablet. The dose was 2 tablets 3 times per day for 1 year, starting on the first day of chemotherapy; in most cases the dose was reduced to 1 tablet 3 times per day after the first year, and was continued indefinitely. The proportion of patients achieving complete remission, partial remission, or stable disease was significantly higher in the enzyme group than in the control group (97.6% vs. 69.7%; p = 0.001). In stage III patients, the proport ion of non-responders was 3.7% in the enzyme group and 38.9% in the control group (p < 0.001). The median survival time in stage III patients was 47 months in the control group and 83 months in the enzyme group (77% increase; p < 0.002), corresponding to a 3-year increase in survival time. The observation period was not long enough to estimate the survival times for patients in stages I and II.

Comment: Proteolytic enzymes have been used for many years in the treatment of various types of cancer, but there is only a small amount of published research supporting its use. The present study has a potential flaw, in that patients who discontinued enzyme treatment (perhaps because they were too sick to continue) were counted as not having received the treatment. In addition, the non-random selection of patients may have biased the results. Nevertheless, the outcome was markedly better in the enzyme group than in the control group, suggesting that enzyme treatment increases the response rate and prolongs survival in patients with multiple myeloma. Although the mechanism of action is not known, it has been suggested that proteolytic enzymes help break through a protective coating produced by cancer cells, thereby giving the immune system a better chance to attack the tumor cells.

Sakalova A, et al. Retrolective cohort study of on additive therapy with on oral enzyme preparation in patients with multiple myeloma. Cancer Chemother Pharmacol 2001;47(Suppl):S38-S44.

COPYRIGHT 2003 The Townsend Letter Group
COPYRIGHT 2003 Gale Group

Return to Multiple myeloma
Home Contact Resources Exchange Links ebay